The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults
University of Florida
45 participants
Sep 12, 2023
INTERVENTIONAL
Conditions
Summary
Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, we will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, and decision-making.
Eligibility
Inclusion Criteria6
- Individuals fluent in English will participate.
- Must report some experience with opioids (e.g., oxycodone, defined as use at least once in the subject's lifetime).
- Be within 20% of their ideal body weight.
- Are not currently experiencing chronic pain (pain on most days during the past 3 months)
- Have a systolic blood pressure of <=140 and diastolic blood pressure of <= 90, and a heart rate <= 90 beats per minute.
- Participants must also have a normal electrocardiogram (EKG) reading and bloodwork indicating no major health contraindications.
Exclusion Criteria4
- Significant current physical disease or major (uncontrolled) psychiatric disorder.
- No self-reported current interest in drug abuse treatment.
- Women who are pregnant or nursing.
- Any severe comorbid illicit substance use disorders or current clinically significant withdrawal for any abused drug excluding nicotine and caffeine.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oxycodone 5mg oral administration
Oxycodone 2.5mg oral administration
Oxycodone 0mg (placebo) oral administration
Intranasal oxytocin administration (48 IU)
Intranasal oxytocin placebo administration
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05761860